CD4 and neoplasm: In a mixed tumor-leukocyte reaction (to endow basal levels of CD4 T cell activation), the EnAd-infected tumor cells also led to much greater stimulation of CD4 T cells than the other treatments (Figure 7), and this suggests that EnAd may be particularly suited to creating an adaptive immune response in human clinical trials.